Hutchmed China Limited (HCM) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Hutchmed china Limited  (NASDAQ: HCM)

Hutchmed China Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Hutchmed China Limited in the fourth quarter 2025?
Hutchmed china Limited achieved a return on average equity (ROE) of 36.84 % in its fourth quarter 2025, this is above HCM's average return on equity of -10.5%.
Hutchmed China Limited shareholder's equity over the 12 months ending in its fourth quarter 2025 are valued at $1,242 million

ROE has advanced compared to 3.4% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 23 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 277, from total ROE ranking in the third quarter 2025 at 1893.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change 62.9 % 62.11 % 63.44 % 62.11 % -
Y / Y Net Income Change 1099.19 % - - - -62.24 %
Net Income (TTM) in Millions 458 38 38 38 38
Return On Equity (TTM) 36.84 % 3.4 % 3.81 % 4.32 % 5 %
HCM's Total Ranking # 277 # 1893 # # #
Equity (TTM) in Millions 1,238 1,251 1,229 1,251 760
Seq. Equity Change -1.07 % 1.81 % -1.77 % 64.66 % -1.54 %
Seq. Net Income Change - - - - -

Back to HCM Management Effectiveness >> HCM's 5 Years Annual ROE >> Compare HCM ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 24
Sector # 51
Overall # 277

Return On Equity Statistics
High Average Low
36.98 %
-10.5 %
-56.59 %
(Dec 31 2025)   (Dec 31 2022)





HCM Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 1,238 760 743 637 1,040
Y / Y Equity Change 62.9 % 2.23 % 16.73 % -38.73 % 100.31 %
Net Income in Millions 458 38 101 -360 -167
Y / Y Net Income Change 1099.19 % -62.24 % - - -
Return On Equity 36.98 % 5.02 % 13.6 % -56.59 % -16.07 %

Back to HCM Management Effectiveness >> HCM's 5 Years Annual ROE >> Compare HCM ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 36.98 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HCM's' Return on Equity at Yahoo Finance
HCM's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HCM's Competitors
Subscribers only: Roe for Hutchmed China Limited's Suppliers
Subscribers only: Return On Equity for HCM's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Tg Therapeutics Inc   101.12 %
Eli Lilly And Company  97.61 %
Amgen Inc   96.65 %
Halozyme Therapeutics Inc   92.67 %
Earth Science Tech Inc   82.09 %
Exelixis Inc   81.25 %
Elite Pharmaceuticals Inc   80.28 %
Zevra Therapeutics Inc   74.63 %
3m Company  71.32 %
Entera Bio Ltd   70.43 %
Aurinia Pharmaceuticals Inc   70.37 %
Idexx Laboratories Inc  69.78 %
Alnylam Pharmaceuticals Inc   69.25 %
Enlivex Therapeutics Ltd  63.85 %
Dariohealth Corp   59.48 %
Nrc Health  58.51 %
Zoetis Inc   56.31 %
Alpha Tau Medical Ltd  55.29 %
Transmedics Group Inc   53.88 %
Pulmatrix Inc   53.50 %
Abeona Therapeutics Inc   53.18 %
Novo Nordisk A  52.79 %
Medinotec Inc   52.76 %
Concentra Group Holdings Parent Inc   47.62 %
Theravance Biopharma inc   46.03 %
Galmed Pharmaceuticals Ltd   43.72 %
Acadia Pharmaceuticals Inc   41.90 %
Arrowhead Pharmaceuticals Inc   41.16 %
Gilead Sciences Inc   41.14 %
Tenet Healthcare Corp  40.89 %

Date modified: 2026-07-07T11:20:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.